Annual Report for the financial year 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Astal Laboratories Limited (formerly Macro International Limited) filed its 32nd Annual Report for FY ending 31st March 2025, with AGM scheduled for 12th September 2025. The company posted a blockbuster year with revenue from operations rising 171.64% to Rs. 6,423.10 Lacs from Rs. 2,364.77 Lacs in FY24. Profit after tax jumped 1,039% to Rs. 892.53 Lacs from Rs. 78.47 Lacs, driven by the ramp-up of its pharmaceutical bulk drug (API) and intermediates business, which it entered just two years ago. The Board did not recommend any dividend, opting to retain surplus for working capital needs. Statutory and Secretarial Auditors gave clean reports with no qualifications, and the company allotted 37.29 lakh convertible warrants on a preferential basis during the year.
Exceptional top-line and bottom-line growth signals strong execution of the company's pivot into bulk drug manufacturing. The non-existent dividend and preferential warrant allotment may dilute shareholders, but robust PAT growth and improving margins are likely positive for the stock and long-term shareholder value.